We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials.
- Authors
Lévy, Bernard I; Mourad, Jean Jacques
- Abstract
Despite a similar beneficial effect on blood pressure lowering observed with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor (AT1R) blocker (ARBs), several clinical trials and meta-analyses have reported higher cardiovascular mortality and lower protection against myocardial infarction with ARBs when compared with ACEIs. The European guidelines for the management of coronary syndromes and European guidelines on diabetes recommend using ARBs in patients who are intolerant to ACEIs. We reviewed the main pharmacological differences between ACEIs and ARBs, which could provide insights into the differences in the cardiac protection offered by these 2 drug classes. The effect of ACEIs on the tissue and plasma levels of bradykinin and on nitric oxide production and bioavailability is specific to the mechanism of action of ACEIs; it could account for the different effects of ACEIs and ARBs on endothelial function, atherogenesis, and fibrinolysis. Moreover, chronic blockade of AT1 receptors by ARBs induces a significant and permanent increase in plasma angiotensin II and an overstimulation of its still available receptors. In animal models, AT4 receptors have vasoconstrictive, proliferative, and inflammatory effects. Moreover, in models with kidney damage, atherosclerosis, and/or senescence, activation of AT2 receptors could have deleterious fibrotic, vasoconstrictive, and hypertrophic effects and seems prudent and reasonable to reserve the use of ARBs for patients who have presented intolerance to ACE inhibitors.
- Subjects
ACE inhibitors; ANGIOTENSINS; ANGIOTENSIN II; CLINICAL trials; RENIN; MYOCARDIAL infarction; HYPERTROPHIC scars
- Publication
American Journal of Hypertension, 2022, Vol 35, Issue 4, p293
- ISSN
0895-7061
- Publication type
Article
- DOI
10.1093/ajh/hpab108